French company seeks to profit from COVID-19
Concept:
MedinCell is a French company seeking to adapt their BEPO® technology to include continuous, injectable/subcutaneous dosing of ivermectin for prophylaxis of COVID-19. This prevention strategy called “pre-exposure prophylaxis” (PrEP).
MedinCell is a French company seeking to adapt their BEPO® technology to include continuous, injectable/subcutaneous dosing of ivermectin for prophylaxis of COVID-19. This prevention strategy called “pre-exposure prophylaxis” (PrEP).
Long Term Goal:
MedinCell's long-term objective aims to produce a patentable, marketable injectable treatment to protect from COVID-19 with a subcutaneous injection that would provide a 1-month time-released supply of ivermectin. MedinCell hopes that their BEPO® technology will form of a small subcutaneous depot of ivermectin under the skin via hypodermic injection. It will act as a mini pump that releases Ivermectin regularly into the system over the course of one month. A 3-month time-released product is also being formulated.
MedinCell's long-term objective aims to produce a patentable, marketable injectable treatment to protect from COVID-19 with a subcutaneous injection that would provide a 1-month time-released supply of ivermectin. MedinCell hopes that their BEPO® technology will form of a small subcutaneous depot of ivermectin under the skin via hypodermic injection. It will act as a mini pump that releases Ivermectin regularly into the system over the course of one month. A 3-month time-released product is also being formulated.
Short Term Study:
To lay the groundwork for their long term goal, the following study is underway: A Randomized, Double-Blind, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Ivermectin in Healthy Volunteers.
This clinical trial aims at validating the safety of consuming ivermectin DAILY in oral form over four weeks to simulate the continuous release of the active ingredient by a long-acting time-released injection. MedinCell hopes that the study will serve as a foundation for the development of the long-acting injectable formulation that can be marketed to a potentially massive worldwide market.
PROBLEM:
MedinCell has received millions of dollars from investors to fund these studies ON HEALTHY PEOPLE while millions of people in the United States and around the world who are suffering and dying from COVID-19 are being denied access to ivermectin in safe, effective, affordable tablet form.
Capitalism at its finest.
To lay the groundwork for their long term goal, the following study is underway: A Randomized, Double-Blind, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Ivermectin in Healthy Volunteers.
This clinical trial aims at validating the safety of consuming ivermectin DAILY in oral form over four weeks to simulate the continuous release of the active ingredient by a long-acting time-released injection. MedinCell hopes that the study will serve as a foundation for the development of the long-acting injectable formulation that can be marketed to a potentially massive worldwide market.
PROBLEM:
MedinCell has received millions of dollars from investors to fund these studies ON HEALTHY PEOPLE while millions of people in the United States and around the world who are suffering and dying from COVID-19 are being denied access to ivermectin in safe, effective, affordable tablet form.
Capitalism at its finest.
Ivermectin in Use Around the World
Ivermectin tablets have already been administered to hundreds of millions of people around the world. Its safety has been demonstrated and documented. Since the beginning of the pandemic, evidence of ivermectin's efficacy against COVID-19 has continued to accumulate.
In combination with other medications and nutritional supplements, ivermectin is also already being used with the approval of health authorities in several countries including Peru, Bolivia, Guatemala and India.
Rather than simply provide safe, affordable, effective and available tablets to people who are suffering and dying NOW, investors hope that MedinCell's BEPO® technology will make it possible to patent, market and profit from a therapy that will deliver Ivermectin continuously for several days, weeks, or months via a one-time subcutaneous (under the skin) injection.
MedinCell
MedinCell is a clinical-stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed.
The large-scale production capacities set up as part of the joint venture formed by MedinCell with Corbion will enable the large-scale supply of the biocompatible polymers required for the production of tens of millions of doses.
In a favorable scenario, MedinCell will apply for market authorization before the end of 2021. The persistence of the pandemic should allow MedinCell to benefit from an accelerated regulatory pathway to market.
In addition, several advanced discussions are underway with public and private partners to fund this program. The company has attracted prestigious partners such as the Bill & Melinda Gates Foundation for past research efforts.
MedinCell is based in Montpellier, France and currently employs more than 130 people.
MedinCell hopes to file for market authorization as early as 2021.
How many people will die from COVID-19 in the meantime?
How many people will die from COVID-19 in the meantime?
Invest in high-tech therapy:
Because there just isn't any profit in prescribing simple, off-patent tablets that are safe and effective.
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86
Louis-Victor Delouvrier
Investor Relations
medincell@newcap.eu
+33 (0)1 44 71 98 53
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 98
